These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21923605)

  • 21. APOE genotype makes a small contribution to warfarin dose requirements.
    Sconce EA; Daly AK; Khan TI; Wynne HA; Kamali F
    Pharmacogenet Genomics; 2006 Aug; 16(8):609-11. PubMed ID: 16847429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
    Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
    Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
    Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
    Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary OA
    Ir J Med Sci; 2014 Jun; 183(2):161-72. PubMed ID: 23800980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.
    Mili FD; Allen T; Wadell PW; Hooper WC; Staercke C; Bean CJ; Lally C; Austin H; Wenger NK
    Future Cardiol; 2018 Jan; 14(1):15-26. PubMed ID: 29218998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.
    Gan GG; Phipps ME; Lee MM; Lu LS; Subramaniam RY; Bee PC; Chang SH
    Ann Hematol; 2011 Jun; 90(6):635-41. PubMed ID: 21110192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.
    Kwon A; Jo SH; Im HJ; Jo YA; Park JY; Kang HJ; Kim HS; Cho HC; Lee YK
    J Thromb Thrombolysis; 2011 Nov; 32(4):467-73. PubMed ID: 21713378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Race influences warfarin dose changes associated with genetic factors.
    Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM
    Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.
    de Oliveira Almeida VC; Ribeiro DD; Gomes KB; Godard AL
    Mol Diagn Ther; 2014 Dec; 18(6):675-83. PubMed ID: 25312789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.
    Gong IY; Tirona RG; Schwarz UI; Crown N; Dresser GK; Larue S; Langlois N; Lazo-Langner A; Zou G; Roden DM; Stein CM; Rodger M; Carrier M; Forgie M; Wells PS; Kim RB
    Blood; 2011 Sep; 118(11):3163-71. PubMed ID: 21725053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
    Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
    Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic determinants of variability in warfarin response after the dose-titration phase.
    Iwuchukwu OF; Ramirez AH; Shi Y; Bowton EA; Kawai VK; Schildcrout JS; Roden DM; Denny JC; Stein CM
    Pharmacogenet Genomics; 2016 Nov; 26(11):510-516. PubMed ID: 27632229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
    Drozda K; Wong S; Patel SR; Bress AP; Nutescu EA; Kittles RA; Cavallari LH
    Pharmacogenet Genomics; 2015 Feb; 25(2):73-81. PubMed ID: 25461246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
    Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
    Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves.
    Chung JE; Chang BC; Lee KE; Kim JH; Gwak HS
    Eur J Clin Pharmacol; 2015 Oct; 71(10):1229-36. PubMed ID: 26257249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.